Liver Cancer Diagnosis
Liver Cancer Diagnosis
Liver cancer diagnosis is imaging-first, combined with a score of how well the liver is working — because in this disease the two answers carry equal weight.
Surveillance: how the disease is meant to be found
For anyone with cirrhosis, chronic hepatitis B or chronic hepatitis C, the standard is a liver ultrasound plus an AFP blood test every six months. This is not a general health check; it is a targeted programme for a group whose annual risk of liver cancer is high enough that regular scanning is worth it.
Surveillance works because liver cancers grow from a liver that is already being watched, which means many are found at a stage where removal or ablation is possible — often a year or more before any symptom would have appeared. Two practical points decide whether it delivers: the interval, which should not drift, and the quality of the imaging. Ultrasound is the usual first test worldwide because it is quick, harmless and inexpensive; it is less reliable in a very scarred liver or in a patient with a large body habitus.
If your ultrasound is technically limited, or if your AFP is rising without a clear cause, the next step is not to wait another six months — it is contrast imaging. The eligibility criteria and intervals are set out in prevention and surveillance.
Multiphase contrast CT or MRI: the central test
When surveillance or a symptom raises suspicion, the diagnostic test is a contrast-enhanced scan of the liver taken in several phases — before contrast, during the arterial phase, in the portal-venous phase and later. The reason is biological: a liver cancer develops its own arterial blood supply, so it brightens early when contrast arrives and then fades while the surrounding liver brightens. That signature — early enhancement with washout — is what identifies the tumour.
Why the phases matter
A single-phase scan can miss the diagnosis entirely. The arterial phase shows the tumour's own blood supply; the venous and delayed phases show whether it washes out and whether the portal vein is involved. Both halves of the pattern are needed before a finding is called typical.
CT or MRI?
Both are used. MRI gives better contrast between tumour and liver tissue and can characterise small or atypical lesions that CT leaves uncertain; it is also better at showing tumour inside the portal vein. CT is faster and remains the commonest first-line study. If one is inconclusive, the other is often the answer.
Findings are reported using a standardised category system (LI-RADS), which grades each lesion from definitely benign to definitely cancer based on its enhancement pattern and size. The category determines whether treatment can proceed, whether closer follow-up is needed, or whether tissue must be obtained. It also gives you and your doctors a common language: a category of 5 in an at-risk liver is treated as cancer, while a category of 3 means watch and repeat.
Blood tests: markers and liver function together
Blood testing in liver cancer has two jobs, and they are equally important.
Tumour markers
AFP is the best known and is used both in surveillance and in follow-up. PIVKA-II (also called DCP) is a second marker that can be raised when AFP is not, which is why the two are often measured together. Neither is a diagnosis on its own: markers rise and fall for many reasons and are interpreted with imaging.
Liver function
Albumin, bilirubin, clotting time, platelets and the presence of ascites or encephalopathy are combined into the Child-Pugh score, and more recently into the ALBI grade. These describe how much working liver remains — the single strongest influence on what treatment is safe to offer.
Underlying liver disease
Hepatitis B and C serology with viral load, and an assessment of how long-standing the liver disease is. This is not background detail: it determines whether antiviral treatment should start now, and it affects how treatment will be tolerated.
Read together, these results often change the plan more than the tumour measurement does. A tumour that could technically be removed may be better treated by ablation if the liver's reserve is borderline; a patient with preserved function may be able to tolerate a more ambitious approach. That judgement is the reason the panel includes hepatology as well as oncology.
When a biopsy is needed — and when it is not
In a patient with cirrhosis whose scan shows a lesion with the typical enhancement pattern, guidelines allow the diagnosis to be made without a needle. This is deliberate: a biopsy carries a small risk of bleeding and of tumour seeding along the needle track, in a liver that often has abnormal clotting. Avoiding an unnecessary invasive test is the safer choice.
Tissue is obtained when it will actually change management — for example when the imaging pattern is atypical, when the underlying liver disease is absent or uncertain, when bile-duct cancer is suspected, or when a result such as a targetable alteration or an immune marker is needed to choose a drug. A biopsy is also occasionally needed to confirm a suspected recurrence or a second primary tumour. When it is done, it is image-guided and performed with the clotting status corrected beforehand.
Staging: how the picture is completed
Staging establishes whether the tumour is confined to the liver, whether it has entered the portal vein or hepatic veins, and whether it has spread beyond the liver. Alongside the liver images, this usually means a CT of the chest and assessment for bone involvement when symptoms suggest it; PET-CT is used selectively rather than routinely, because hepatocellular carcinoma is not always PET-avid.
The result is expressed in the systems that guide treatment — the BCLC classification internationally, and the Chinese national staging system, which is widely used in practice here. Both combine the tumour, the liver and the patient's general condition, because a plan that ignores any one of the three will be wrong. Once staging is complete, the multidisciplinary panel issues one unified recommendation rather than a menu of departmental opinions: see the treatment guide for what each stage usually means in practice.
Preparing for a review from abroad
For international patients, the work-up can largely be assembled before travelling — and the more complete the file, the more definite the answer.
- Digital imaging — multiphase contrast CT or MRI of the liver in DICOM format, plus any earlier studies for comparison and chest imaging if available
- Blood results — AFP and PIVKA-II, liver function tests including albumin and bilirubin, clotting studies, full blood count, and hepatitis B and C serology with viral load
- Pathology and molecular reports — any biopsy report, and any molecular or immune-marker testing already performed, including FGFR2 and IDH1 results if bile-duct cancer is suspected
- Treatment history — a short timeline of what has been done, the drugs and doses used, the response, and any side effects that led to a change
- Current medication list — including antivirals, diuretics, blood thinners and any herbal product, since several common supplements interact with liver drugs or are themselves toxic to a damaged liver